Biovail to shutter Dublin plant; Sanofi's German ops chief quitting;

> Another day, another Roche deal. The pharma giant announced yesterday ning that it is paying $189 million to buy Canada's Arius Research, a move that will help beef up its portfolio of experimental therapies for cancer and inflammation. Report

> Canadian pharmaceutical company Biovail is planning to close its plant in Dublin, Ireland, where it employs almost 50 people. Report

> The head of Sanofi-Aventis' German operations Heinz-Werner Meier will leave his post at the end of the year, Financial Times Deutschland reported. Report

> Bristol-Myers Squibb tapped Quentin Roach as senior vice president and chief procurement officer. Report

> Elan reported growing sales and narrowing losses in second-quarter results Thursday, citing momentum for its multiple sclerosis-fighting drug, Tysabri. Report

> Drug distributor AmerisourceBergen on Thursday posted a fiscal third-quarter loss of $108 million on a charge associated with the the sale of its struggling PMSI workers' compensation business. But adjusted earnings beat analyst estimates, and the company boosted its outlook for the year. Report

> There's a considerable amount of attention being focused on Exelixis' move to launch a late-stage study of XL184. Exelixis report

> The University of Oxford and Emergent BioSolutions have formed a joint venture--The Oxford-Emergent Tuberculosis Consortium--to further develop MVA85A, an experimental vaccine for the prevention of tuberculosis. Report

> The FDA has handed NexMed a non-approvable letter for its experimental topical therapy for ED. NexMed report

> Illumina has struck a $60 million deal to enhance its genetic sequencing technology with the acquisition of Avantome. Report

> Researchers are trying to find out why a vaccine for Alzheimer's would be able to eliminate the beta-amyloid plaque long considered responsible for the disease without actually curing the disease. Report

> Merck's decision to pump $300 million into an expansion of its Durham, NC vaccine facility is seen by analysts as part of a coordinated effort to solidify a leading role in a booming global vaccines market. Merck report

> A new cancer vaccine made from genetically engineered tobacco leaves has been found safe in a small, early-stage trial. Report

> Dynavax Technologies and Novartis Vaccines and Diagnostics are teaming up on an effort to develop a new universal flu vaccine. report

And Finally... Botox-pushing brides get their attendants to the medi-spa on time. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.